比利时2023/24与2024/25冬季成人RSV、流感或COVID-19住院患者的特征与结局
该研究纳入比利时九家哨点医院两个冬季季因严重急性呼吸道感染住院的2806名成人,比较实验室确诊RSV、流感或COVID-19患者的特征与结局。RSV患者病程与流感或COVID-19相当且住院死亡率更高,尤以高龄者为著,提示应重视老年及共病人群的RSV疫苗接种。
要点
- RSV住院患者死亡率高于流感或COVID-19患者
- 流感患者较RSV或COVID-19患者更年轻且共病更少
- 年轻成人调整后共病相对更多、ICU入住率更高但死亡率更低
核心结论
- RSV感染患者病程与流感或COVID-19患者相当,且住院死亡率更高,尤其随年龄增长。
- 研究结果强调老年人和共病人群接种RSV疫苗的重要性,并与既有的流感和COVID-19疫苗接种策略并列。
研究设计与样本
- 纳入2023/24和2024/25冬季季比利时九家哨点医院因严重急性呼吸道感染住院的成人(≥18岁)。
- 比较实验室确诊RSV、流感或COVID-19患者在人口学、共病、并发症和结局方面的差异,并比较18-64岁与≥65岁成人。
- 采用多因素分析。
主要发现
- 2806名患者中,535名(19.1%)为RSV感染,1694名(60.4%)为流感,577名(20.6%)为COVID-19。
- 流感患者平均年龄68.9岁、共病比例89.7%,显著低于RSV患者(73.8岁;95.8%)和COVID-19患者(74.0岁;93.6%)。
- COVID-19患者并发症发生率40.8%,显著低于RSV患者48.9%和流感患者45.2%。
- RSV患者住院死亡率11.9%,高于流感患者7.3%(p=0.089)和COVID-19患者6.9%(p=0.037)。
- 各病原体间,年轻成人在调整一般人群差异后共病相对更多,住院时间更短、死亡率更低,但ICU入住率更高。
临床怎么用
- 应重视老年人和共病人群的RSV疫苗接种,与季节性流感和COVID-19疫苗接种策略并行。
- 对RSV住院患者尤其是高龄者应关注较高死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDSevere acute respiratory infections (SARI) cause substantial disease burden in older adults and those with comorbidities.AIMTo inform Belgian vaccination policies, we aimed to compare risk profiles and outcomes of influenza, COVID-19 and RSV infections and examine age-related differences.METHODSAdults (≥ 18 years) hospitalised with SARI in nine Belgian sentinel hospitals during the 2023/24 and 2024/25 winter seasons were included. Patients with laboratory-confirmed RSV infection, influenza or COVID-19 were compared in terms of demographics, comorbidities, complications and outcomes. Adults 18-64 years were compared with those ≥ 65 years. Multivariate analyses were applied.RESULTSAmong 2,806 patients, 535 (19.1%) had RSV infection, 1,694 (60.4%) influenza and 577 (20.6%) COVID-19. Patients with influenza were significantly younger (mean age 68.9 years) and had significantly fewer comorbidities (89.7%) than patients with RSV (73.8 years; 95.8%) or COVID-19 (74.0 years; 93.6%). Patients with COVID-19 experienced significantly fewer complications (40.8%) than patients with RSV (48.9%) or influenza (45.2%). Patients with RSV had higher in-hospital mortality (11.9%) than patients with influenza (7.3%; p = 0.089) or COVID-19 (6.9%; p = 0.037). Across pathogens, younger adults had relatively more comorbidities after adjusting for differences in the general population. They had shorter hospital stays and lower mortality, but higher intensive care unit admission rates.CONCLUSIONPatients with RSV infection had a disease course comparable to patients with influenza or COVID-19 and a higher mortality rate, especially with increasing age. These findings highlight the importance of RSV vaccination in older adults and those with comorbidities, alongside established vaccination strategies for seasonal influenza and COVID-19.
引用
- Lafort Y, Dambre C, Dockx Y, et al. Characteristics and outcomes of adult patients hospitalised with RSV infection, influenza or COVID-19 in Belgium, winter seasons 2023/24 and 2024/25. Euro Surveill. 2026. PMID: 42757413. doi:10.2807/1560-7917.ES.2026.31.37.2600088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。